MK-677 Research for Bone Density
An evidence-based overview of research examining MK-677 in the context of bone density. This page synthesizes findings from peer-reviewed literature.
Research Summary
Clinical trials evaluated MK-677 for bone metabolism in elderly populations. The sustained increase in GH and IGF-1 reliably stimulates markers of bone formation and resorption (osteocalcin, NTx). Effects on actual bone mineral density were limited. In an 18-month trial of postmenopausal osteoporotic women, MK-677 added to alendronate increased BMD only at the femoral neck versus alendronate alone, with no significant gain at the lumbar spine, total hip, or total body. MK-677 alone increased turnover markers but did not demonstrate broad BMD benefit. Long-term safety data is limited, and MK-677 was not approved for osteoporosis. Concerns about glucose tolerance may limit use in elderly patients.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. MK-677 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.